2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-100228A
    SKF89976A hydrochloride 85375-15-1 99.70%
    SKF89976A hydrochloride is a selective GABA transporter (GAT-1) inhibitor with IC50s of 0.28 μM, 137.34 μM and 202.8 μM for GAT-1, GAT-2 and GAT-3 in CHO cells, respectively.
    SKF89976A hydrochloride
  • HY-100530C
    Sp-cAMPS sodium salt 142439-95-0 99.45%
    Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a Ki of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC50 of 40 μM.
    Sp-cAMPS sodium salt
  • HY-100781A
    L-AP4 23052-81-5 ≥99.0%
    L-AP4 (L-APB) is a potent and specific agonist for the group III mGluRs, with EC50s of 0.13, 0.29, 1.0, 249 μM for mGlu4, mGlu8, mGlu6 and mGlu7 receptors, respectively.
    L-AP4
  • HY-108235B
    (Rac)-Lanicemine 61890-25-3 ≥98.0%
    (Rac)-Lanicemine ((Rac)-AZD6765) is the racemate of Lanicemine. Lanicemine (AZD6765) is a low-trapping NMDA channel blocker (Ki of 0.56-2.1 μM for NMDA receptor; IC50s of 4-7 μM and 6.4 μM in CHO and Xenopus oocyte cells, respectively). Antidepressant effects.
    (Rac)-Lanicemine
  • HY-109590A
    Arachidonic acid sodium salt 6610-25-9 ≥99.0%
    Arachidonic acid (Immunocytophyt) sodium salt is a polyunsaturated omega-6 fatty acid and a major constituent of biomembranes. Arachidonic acid sodium salt also acts as the substrate for various lipid mediators, such as prostaglandins (PGs). Arachidonic acid sodium salt improves cognitive response and cardiovascular function.
    Arachidonic acid sodium salt
  • HY-120081A
    Metixene hydrochloride hydrate 7081-40-5 ≥98.0%
    Metixene (Piperidine) hydrochloride hydrate is an anticholinergic and antiparkinsonian agent. Metixene hydrochloride hydrate potently inhibits binding of quinuclidinyl benzilate (QNB) with the muscarinic receptor, IC50 and Ki values of 55 nM and 15 nM, respectively. Metixene hydrochloride hydrate can be used for the research of parkinsonian.
    Metixene hydrochloride hydrate
  • HY-132857A
    ZXH-4-130 TFA 2711006-67-4 99.71%
    ZXH-4-130 TFA is a highly potent and selective degrader of CRBN. ZXH-4-130 is a CRBN-VHL compound (hetero-PROTAC). ZXH-4-130 TFA induces ~80% CRBN degradation at 10 nM in MM1.S cells.
    ZXH-4-130 TFA
  • HY-14608S5
    L-Glutamic acid-13C5 55443-55-5 ≥98.0%
    L-Glutamic acid-13C5 is the 13C-labeled L-Glutamic acid. L-Glutamic acid acts as an excitatory transmitter and an agonist at all subtypes of glutamate receptors (metabotropic, kainate, NMDA, and AMPA). L-Glutamic acid shows a direct activating effect on the release of DA from dopaminergic terminals.
    L-Glutamic acid-13C5
  • HY-150270A
    NP-1815-PX sodium 1239578-80-3 99.62%
    NP-1815-PX sodium is a potent and selective P2X4R antagonist. NP-1815-PX sodium has anti-inflammatory activity, and can relieve pain in chronic pain models. NP-1815-PX sodium also inhibits guinea pig tracheal/bronchial smooth muscle (TSM and BSM) contractions.
    NP-1815-PX sodium
  • HY-W010970
    5'-Guanylic acid disodium salt 5550-12-9 ≥98.0%
    5'-Guanylic acid disodium salt is the disodium salt form of 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid disodium salt is a purine nucleotide that participates in physiological processes such as energy metabolism, signal transduction, and gene expression regulation. 5'-Guanylic acid disodium salt regulates the expression of genes related to fatty acid metabolism. 5'-Guanylic acid disodium salt is the weak agonist for ionotropic glutamate receptors (iGluR), reduces the activity of the glutamatergic system and exhibits neuroprotective effect. 5'-Guanylic acid disodium salt also causes neuronal cell death at high concentrations.
    5'-Guanylic acid disodium salt
  • HY-W012906
    L-Allylglycine 16338-48-0 ≥98.0%
    L-Allylglycine (L-2-Allylglycine) is an amino acid derivative. L-Allylglycine is an inhibitor for glutamate decarboxylase (GAD) that reduces the GABA biosynthesis in the brain. L-Allylglycine exhibits convulsant activity.
    L-Allylglycine
  • HY-W013075
    Rutin trihydrate 250249-75-3
    Rutin (Rutoside) trihydrate is a multifunctional natural flavonoid glycoside. Rutin trihydrate has been demonstrating excellent antioxidant, anti-inflammatory, anti-diabetic, and anti-carcinogenic properties. Cardioprotective and neuroprotective activities .
    Rutin trihydrate
  • HY-W013150
    Alpidem 82626-01-5 99.70%
    Alpidem selectively binds to α1β2γ2 subunit-containing GABAA receptor with an IC50 of 17 nM and exerts anxiolytic effect.
    Alpidem
  • HY-W044764
    2-Benzylsuccinic acid 884-33-3 99.41%
    2-Benzylsuccinic acid (DL-Benzylsuccinic acid) is an orally active carboxypeptidase A and Nna1 inhibitor. 2-Benzylsuccinic acid reduces cold hyperalgesia. 2-Benzylsuccinic acid can be used for the researches of neuropathic pain, non-alcoholic steatohepatitis.
    2-Benzylsuccinic acid
  • HY-14840
    Phenylpiracetam 77472-70-9 99.91%
    Phenylpiracetam(Phenotropyl; Phenotropil) is a phenylated derivative of the nootropic drug piracetam.
    Phenylpiracetam
  • HY-15069
    Fanapanel 161605-73-8 99.34%
    Fanapanel (ZK200775) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively.
    Fanapanel
  • HY-15653
    Filorexant 1088991-73-4 99.27%
    Filorexant (MK-6096) is an orally bioavailable potent and selective reversible antagonist of OX1 and OX2 receptor(<3 nM in binding).
    Filorexant
  • HY-111973
    Phaseic acid 24394-14-7 ≥98.0%
    Phaseic acid is a Abscisic acid terpenoid catabolite that can able to activate a subset of Abscisic acid repectors. Phaseic acid is a plant hormone associated with photosynthesis arrest and abscission. Phaseic acid is the antagonist for NMDA-type glutamate receptor (NMDAR) that inhibits NMDAR currents with an IC50 of 34.37 μM. Phaseic acid reduces intracellular calcium influx, and exhibits neuroprotective effect.
    Phaseic acid
  • HY-13204A
    Biperiden 514-65-8 99.74%
    Biperiden (KL 373) is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden has the potential for the research of Parkinson's disease and other related psychiatric disorders.
    Biperiden
  • HY-W011727
    Pyridoxal 5'-phosphate hydrate 853645-22-4 99.76%
    Pyridoxal 5'-phosphate hydrate, the active form of vitamin B6, is an essential cofactor for multiple enzymes, including aromatic l-amino acid decarboxylase that catalyzes the final stage in the production of the neurotransmitters dopamine and serotonin. Pyridoxal 5'-phosphate hydrate is the most important coenzyme variant in the process of vitamin B6 intracellular phosphorylation and is interconvertible with other variants, including pyridoxine 5′‐phosphate (PNP) and pyridoxamine 5′-phosphate (PMP).
    Pyridoxal 5'-phosphate hydrate
Cat. No. Product Name / Synonyms Application Reactivity